

Supplementary material legends.

Supplementary material Figure 1. Flow chart of patients in whom serum was available.

Supplementary material Figure 2. Normal quantile plot of the ratio: serum thymidine kinase 1 concentration (sTK1) 48h post-/pre-treatment at cycle 1 in 131 patients with localized breast cancer subjected to neoadjuvant chemotherapy with docetaxel + epirubicin. sTK1 was measured with the sandwich TK210 ELISA, AroCell AB, Uppsala, Sweden.

Supplementary material Figure 3a, 3b. Bivariate analysis of serum kinase 1 concentration (sTK1), ng/ml, 48h post-/pre-treatment at cycle 1 in 131 patients with localized breast cancer. The patients were subdivided by the median of the ratio: sTK1 48h post-/pre-treatment. a) 65 patients with sTK1 post-/pre-treatment ratio <1.12, b) 66 patients with sTK1 48h post-/pre-treatment ratio >1.12. Linear regressions: a) $r = 0.73$; $p < 0.0001$. b) $r = 0.83$; $p < 0.0001$.

Supplementary material

Figure 1.


Flow chart

Explanation of missing data among 150 patients with breast cancer, initially recruited for the PROMIX study.

Study start		n=150
Death from toxicity refused participation	n=2	n=148
Missing sTK 1 value at baseline	n=9	n=139
Missing sTK1 value 48 h after treatment 1	n=8	n=131
Missing sTK 1 value before treatment 2	n=67	n=64
Missing sTK 1 value 48h after treatment 2	n=1	n=63
Missing sTK1 before treatment 3	n=4	n=59
Missing sTK values 48h after treatment 3	n=0	n=59
Missing sTK1 before treatment 4	n=1	n=58
Missing sTK values 48h after treatment 4	n=4	n=54


Supplementary material

Figure 2.



Supplementary material

Figure 3 a.



Supplementary material

Figure 3 b.

